Apixaban for Stroke Prevention in Atrial Fibrillation: A Review of the Clinical Trial Evidence

References

• . Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40, ix
   PubMed Web of Science ®Google Scholar
• . Miyasaka Y, Barnes ME, Gersh BJ, . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125
   PubMed Web of Science ®Google Scholar
• . Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–1539
   PubMed Web of Science ®Google Scholar
• . Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57–64
   PubMed Web of Science ®Google Scholar
• . van Weert HC. Diagnosing atrial fibrillation in general practice. BMJ. 2007;335(7616):355–356
   PubMedGoogle Scholar
• . Lloyd-Jones D, Adams R, Carnethon M, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–486
   PubMed Web of Science ®Google Scholar
• . Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–988
   PubMed Web of Science ®Google Scholar
• . Go AS, Hylek EM, Phillips KA, . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
   PubMed Web of Science ®Google Scholar
• . Hannon N, Sheehan O, Kelly L, . Stroke associated with atrial fibrillation—incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis. 2010;29(1):43–49
   PubMed Web of Science ®Google Scholar
• . Marini C, De Santis F, Sacco S, . Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–1119
   PubMed Web of Science ®Google Scholar
• . Fuster V, Rydén LE, Cannom DS, ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–e354
   PubMed Web of Science ®Google Scholar
• . van Walraven C, Hart RG, Wells GA, . A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med. 2003;163(8):936–943
   PubMedGoogle Scholar
• . Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke. 2008;39(1):7–9
   PubMed Web of Science ®Google Scholar
• . Reynolds MW, Fahrbach K, Hauch O, . Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest. 2004;126(6):1938–1945
   PubMed Web of Science ®Google Scholar
• . Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–252
   PubMed Web of Science ®Google Scholar
• . Reynolds MR, Shah J, Essebag V, . Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538–543
   PubMed Web of Science ®Google Scholar
• . Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–1074
   PubMed Web of Science ®Google Scholar
• . van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and meta-regression. Chest. 2006;129(5):1155–1166
   PubMed Web of Science ®Google Scholar
• . Wan Y, Heneghan C, Perera R, . Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91
   PubMed Web of Science ®Google Scholar
• . Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009;2(6):591–597
   PubMed Web of Science ®Google Scholar
• . Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol. 2010;25(4):312–320
   PubMed Web of Science ®Google Scholar
• . Piccini JP, Hernandez AF, Zhao X, ; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54(14):1280–1289
   PubMed Web of Science ®Google Scholar
• . Gage BF, Boechler M, Doggette AL, . Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822–827
   PubMed Web of Science ®Google Scholar
• . Albers GW, Yim JM, Belew KM, . Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156(20):2311–2316
   PubMedGoogle Scholar
• . Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927–934
   PubMed Web of Science ®Google Scholar
• . Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM. 2007;100(5):263–269
   PubMed Web of Science ®Google Scholar
• . Fang MC, Go AS, Chang Y, . Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700–705
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Ezekowitz MD, Yusuf S, ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
   PubMed Web of Science ®Google Scholar
• . Patel MR, Mahaffey KW, Garg J, ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891
   PubMed Web of Science ®Google Scholar
• . Granger CB, Alexander JH, McMurray JJ, ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–982
   PubMed Web of Science ®Google Scholar
• . Connolly SJ, Eikelboom J, Joyner C, ; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–817
   PubMed Web of Science ®Google Scholar
• . Ruff CT, Giugliano RP, Antman EM, . Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–641
   PubMed Web of Science ®Google Scholar
• . ClinicalTrials.gov. A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin. http://clinicaltrials.gov/ct2/show/NCT00938730?term=YM-150&rank=5. Accessed August 17, 2011
   Google Scholar
• . ClinicalTrials.gov. A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter. http://clinicaltrials.gov/ct2/show/NCT01229254?term=betrixaban&rank=3. Accessed August 29, 2011
   Google Scholar
• . Garnock-Jones KP. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11(1):57–72
   PubMed Web of Science ®Google Scholar
• . Guay DR. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists? Hosp Pract (Minneap). 2011;39(1):105–125
   PubMedGoogle Scholar
• . Alexander JH, Lopes RD, James S, . Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708
   PubMed Web of Science ®Google Scholar
• . Lopes RD, Alexander JH, Al-Khatib SM, ; ARISTOTLE Investigators. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–339
   PubMed Web of Science ®Google Scholar
• . Eikelboom JW, O'Donnell M, Yusuf S, . Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159(3):348–353.e1
   PubMed Web of Science ®Google Scholar
• . Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478–492
   PubMed Web of Science ®Google Scholar
• . Pinto DJ, Orwat MJ, Koch S, . Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339–5356
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22
   PubMed Web of Science ®Google Scholar
• . Raghavan N, Frost CE, Yu Z, . Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74–81
   PubMed Web of Science ®Google Scholar
• . Wang L, Zhang D, Raghavan N, . In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448–458
   PubMed Web of Science ®Google Scholar
• . Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41–57
   PubMed Web of Science ®Google Scholar
• . Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–1271
   PubMed Web of Science ®Google Scholar